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Galectin-3-binding glycomimetics that strongly reduce 
bleomycin-induced lung fibrosis and modulate intracellular 
glycan recognition 
T. Delaine,[a] P. Collins,[b] A. MacKinnon,[c] G. Sharma,[d] J. Stegmayr,[d] V. K. Rajput,[a] S. Mandal,[a] I. 
Cumpstey,[a] A. Larumbe,[a] B. A. Salameh,[a]† B. Kahl-Knutsson,[d] H. van Hattum,[e] M. v. 
Scherpenzeel,[e]‡ R. J. Pieters,[e] T. Sethi,[f] H. Schambye,[g] S. Oredsson,[h] H. Leffler,[d] H. Blanchard,*[b] 
and U. J. Nilsson*[a] 
 
Abstract: Discovery of glycan-competitive galectin-3-binding 
compounds that attenuate lung fibrosis in a murine model and that 
block intracellular galectin-3 accumulation at damaged vesicles, 
hence revealing galectin-3-glycan interactions being involved in 
fibrosis progression and in intracellular galectin-3 activities is 
reported. Sixteen 3,3´-bis-(4-aryl-triazol-1-yl)-thiodigalactosides were 
synthesized and evaluated as antagonists of galectin-1, 2, 3, 4 N-
terminal, 4 C-terminal, 7, 8 N-terminal, 9 N-terminal, and 9 C-
terminal domains. Compounds displaying low-nM affinities for 
galectin-1 and 3 were identified in a competitive fluorescence 
anisotropy assay. X-ray structural analysis of selected compounds in 
complex with galectin-3 and galectin-3 mutant binding experiments 
revealed that both aryl-triazolyl moieties and fluoro-substituents of 
the compounds are involved in key interactions responsible for the 
exceptional affinities for galectin-3. The most potent galectin-3 
antagonist was demonstrated to act in an assay monitoring galectin-
3 accumulation upon amitriptyline-induced vesicle damage, 
visualizing a biochemical/medical relevant intracellular lectin-
carbohydrate binding event and that it can be blocked by a small 
molecule. The same antagonist administered intratracheally 
attenuated bleomycin-induced pulmonary fibrosis in a mouse model 
with a dose-response profile comparing favorably to orally 
administration of the marketed anti-fibrotic compound pirfenidone. 
Introduction 
The galectins are a family of proteins that have the ability to 
cross-link -D-galactopyranoside-containing glycoproteins (and 
other glycoconjugates) to form lattices[1] and thereby modulate 
glycoprotein localization, transport, and residence times in 
cellular compartments and at surfaces.[2] Cross-linking of 
glycoproteins by galectins can occur due to the galectins’ 
capability to present multiple carbohydrate recognition sites 
(CRD) depending on their type. Prototype galectins (1, 2, 7, 10, 
11, 13, 14, and 15) contain one CRD but dimerize depending on 
their concentration and ligand density. The tandem-repeat 
galectins (4, 5, 6, 8, 9, and 12) contain and present two CRD’s, 
and the chimera-type galectin-3 CRD is linked to a 
glycine/proline-rich collagen-like N-terminal domain that enables 
oligomerization. 
This organizational lattice-forming role of the galectins 
influences glycoprotein activities and the duration thereof, as 
well as glycoprotein intracellular trafficking and sorting. This 
manifests itself in different effects on the cellular level that 
depend on a match between galectin type and expression, as 
well as on the glycan structures in the cell. For example, 
galectin-glycoconjugate interactions control cell properties and 
functions, cell adhesion, have immunomodulatory effects[3] and 
effects on tumor growth and metastases.[4] The cellular 
mechanisms and roles in inflammation and cancer point to the 
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use of galectin CRD antagonists as therapeutic agents and 
several ex vivo[5] and in vivo[6] studies of the most studied and 
well characterized galectin-3 have corroborated such 
hypotheses. 
Among attempts to develop small and drug-like molecules as 
galectin-3 antagonists, substitution of galactose[6a, 7] (as such, or 
part of lactose or N-acetyl-lactosamine (LacNAc)) and 3,3-di-
substitution of thiodigalactoside[8] have proven to be successful. 
In particular, high-affinity small-molecule galectin-3 antagonists 
with sub-µM affinities have been discovered by appending 
aromatic amido groups or 4-amido-1,2,3-triazolyl groups at both 
C-3 carbons in thiodigalactoside.[8a, 8b, 8d] Here, we present 4-
aryl-1,2,3-triazolyl thiodigalactoside-based derivatives as 
significantly improved antagonists with selectivity for galectin-1 
and 3. Furthermore, an investigation based on three X-ray 
structures of galectin-3 in complex with inhibitors and on 
galectin-3 mutant studies revealed that the aryl-triazolyl groups 
form affinity-enhancing interactions with arginine side-chains 
and with ß-strand backbones. One selected compound was 
demonstrated to function intracellularly in an amitriptyline-
induced vesicle damage assay and to reduce fibrosis levels in a 
murine bleomycin lung fibrosis model. 
Results and Discussion 
Synthesis 
The ditriazolyl-thiodigalactosides 3-10 and 12 were synthesized 
by Cu(I)-catalyzed cycloadditions between the known diazide 1[9] 
and phenylacetylenes (Scheme 1), while synthesis of the 
unsubstituted phenyltriazole 2 and the phenoxyphenyltriazole 11 
have been reported earlier[10] (Table 1). The 1-naphthyl-triazole 
17 was synthesized essentially following a previously published 
alternative procedure[8d] that involved cycloaddition of 1-
ethynylnaphthalene with the acetylated galacto azide 13[11] to 
give the triazole 14. Bromination of 14 and subsequent double 
substitution of the bromide 15 with sodium sulfide resulted in the 
thiodigalactoside 16 in a moderate yield. De-O-acetylation of 16 
gave the target 1-naphthyl-triazole 17. 
 
Galectin affinities and structure-activity relationships 
With a panel of bis-aryltriazolyl thiodigalactosides 2-12 and 17 at 
hand, affinities towards galectin-1, 2, 3, 4 N- and C-terminal 
domains, 7, 8 N-terminal domain, and 9 N- and C-terminal 
domains were determined in a competitive protein-binding assay 
based on fluorescence anisotropy as earlier described in 
detail.[12] Except for galectin-8N, all investigated galectins bound 
all, or most, of the inhibitors 2-12 and 17 with affinities 
significantly greater than those of the parent unsubstituted 
thiodigalactoside (Table 1). Galectin-1 bound all phenyl-triazoles, 
unsubstituted or with smaller substituents, (2-9) with indeed high 
affinities, while larger substituents (10 and 11) significantly 
reduced affinity. Interestingly, 3- and 4-fluorinated phenyl 
compounds 4 and 5 turned out to be the only ones better than 
the unsubstituted phenyl 2 and the 2-fluorophenyl derivative 3, 
with dissociation constants as low as 12 nM (3-fluorophenyl 4).  
 
Scheme 1. Reagents and conditions: (a) Alkyne, CuI, Et3N, DMF; (b) Alkyne, 
CuI, DIPEA, toluene, 65-80°C; (c) HBr/AcOH; (d) Na2S, MS 4Å, MeCN; (e) 
BuNH2, MeOH. 
This suggests that one or both of the galectin-1 subsites that 
accommodate the phenyl groups of 2-11 are tight with limited 
possibilities for substitutions as suggested based on earlier 
analyses of 2 and 11.[10] The preference for substitution position 
of the fluorophenyl derivatives 3-5 (m<p<o) is reflected in the 
corresponding trifluoromethyl series 7-9, albeit at somewhat 
higher Kd values. Although the fluorophenyl-carrying 4 and 5 
indeed reach low nM affinities for galectin-1, more noteworthy is 
the even higher affinity of the thienyl compound 12. This 
compound provided near quantitative inhibition at all 
concentrations tested and an accurate dissociation constant 
could not be reliably calculated. Hence, the dissociation constant 
could only be estimated to be less than 10 nM, which is at least 
2400–fold better than the reference unsubstituted 
thiodigalactoside and natural disaccharide ligands. 
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Table 1. Dissociation constants (µM) for 2-12, and 17 and galectin-1, 2, 3, 4, 4 
N-terminal domain, 4 C-terminal domain, 7, 8 N-terminal domain, and 9 N- and 























































































































































































































































































[a] Not determined. [b] Thiodigalactoside.  
      
In stark contrast, galectin-2 was inhibited with only micromolar 
Kd values by any of 2-12 and 17. The best compound, the 2-
fluorophenyl compound 3, reached only a moderate affinity of 
about 1 µM, which is nevertheless significantly better than the 
parent unsubstituted thiodigalactoside reflecting the presence of 
positive interactions between 2-17 and this galectin. Galectin-3 
was well inhibited by several compounds and interestingly 
showed a selectivity profile similar to galectin-1; phenyl moieties 
carrying small substituents (2-9), as well as the thienyl moiety 
(12), conferred high affinity, while phenyls carrying larger 
substituents (10-11), as well as the naphthyl (17), were less 
efficiently bound by this galectin. A notable difference is, 
however, that while the biphenyl 10 is virtually detrimental to 
binding (as for galectin-1), the 4-phenoxy-substituted phenyl 11 
is reasonably well tolerated by galectin-3, with a sub-µM affinity, 
which is not the case for galectin-1. Hence, compound 11 
displays, as earlier reported,[10] an important more than 50-fold 
selectivity for galectin-3 over galectin-1. The reverse situations 
holds for the thienyl 12, which inhibits galectin-3, albeit with an 
affinity of 65 nM, but still less well than galectin-1. Hence, the 
thienyl derivative 12 has a clear selectivity for galectin-1 over 
galectin-3 and thus through proper choice of aryl substituents on 
the triazole rings, selectivity for galectin-1 (by 12) or galectin-3 
(by 11) is achieved. 
Both CRD of the tandem-repeat galectin-4 were evaluated and 
the N-terminal domain did recognize compounds 2-12 and 17 
with moderate affinities in the low-medium µM range, which for 
all compounds is better than the parent thiodigalactoside. 
Reflecting the difference in fine-specificity between the two 
galectin-4 domains, the C-terminal domain revealed mid-nM 
affinities for several compounds. As observed for galectin-1 and 
3, aryltriazoles carrying no or smaller substitutents at the aryl 
moiety (2-5 and 12) were identified as the best inhibitors. Again, 
this suggests that one or both of the aryl-accommodating sites of 
galectin-4C can harbor only smaller structures. The 4-
fluorophenyl derivative 5 stands out as a most potent galectin-
4C with a Kd of 73 nM, which suggests a specific fluorine 
interaction and/or an ideal steric fit by the 4-fluoro substituent. 
Most likely, efficient inhibition of one domain[13] will be sufficient 
to block physiological/biological effects by galectin-4. Galectin-7 
binding is enhanced by the 4-aryl-triazolyl groups of 2-9, 12, and 
17, while the sterically more demanding compounds 10-11 are 
virtually non-binding. Similar observations were made for 
galectin-9N and 9C, which both bind several inhibitors with sub 
to low µM affinities. In contrast to galectin-4, no clear selectivity 
between the two domains of galectin-9 was observed. 
Overall, the 4-aryl-triazolyl thiodigalactosides 2-12 and 17 
delivered inhibitors significantly more potent than 
thiodigalactoside itself against galectin-1, 2, 3, 4N, 4C, 7, 9N, 
and 9C and more potent than the corresponding galactoside 
monosaccharide derivative against galectin-3, 7, and 9N (c.f. e.g. 
the monosaccharide corresponding to 2 show Kd of 150, 1700, 
and 1300 µM, respectively, against these four galectins[7a,8d]). In 
particular, galectin-1 and 3 were well inhibited with several 
compounds showing low nM affinity. The inhibition potency 
against galectin-3 even surpassed our earlier described 
corresponding 4-amido-triazolyl-[8d] and 4-aryl-triazolyl-
thiodigalactoside[10] derivatives. Several compounds indeed 
possess a clear selectivity for these two galectins, while the 
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selectivity between them is limited except for the thienyl 
derivative 12 and the phenoxy derivative 11 that displayed 
moderate selectivity for galectin-1 and 3, respectively. 
 
Structural studies 
The X-ray structures were determined of three selected high-
affinity compounds, the 3- and 4-fluophenyl derivatives 4 and 5 
and the thienyl derivative 12, in complex with galectin-3. Initial 
refinements of X-ray diffraction data (1.5–1.6 Å resolution, 
Supplementary Table S1) produced clear difference electron 
density within the galectin binding sites revealing the bound 
ligands 4, 5, and 12 (Figure 1). In all cases, electron density is 
clearly evident for the thiodigalactoside core of all three ligand 4, 
5, and 12 (except for the solvent orientated C6 hydroxyl), and for 
both triazole rings. The thiodigalactoside core of each ligand 4, 5, 
and 12 is in an identical binding mode to that observed in the 
previously reported galectin-3-thiodigalactoside complex[14] and 
forms identical protein–ligand interactions, confirming that they 
do not act as divalent ligands. Electron density is also defined 
for the aromatic rings extending from one of the triazole C4 
atoms of 4, 5, and 12 towards the Arg144 side chain. The 
second thiophene or fluorophenyl rings of the ligands 4, 5, and 
12, positioned above the salt bridge between Glu165 and 
Arg186, are less clearly defined by the initial difference electron 
density maps compared to the rest of the ligand (upper region of 
the ligands in Figure 1a–c). The position of the thiophene ring of 
12 and the 3-fluorophenyl ring of 4 is evident in the region near 
Glu165 and Arg186 in difference electron density maps when 
scaled to 2.5 σ (calculated prior to addition of the ligand to the 
model) and refinements with the ligand included in the model 
show the thiophene and 3-fluorophenyl rings defined by 
2mFo−DFc electron density when scaled at 0.7 σ. Additional 
weak 2mFo−DFc electron density appears near Glu165 and 
Arg186 of 4 after refinement, indicating a possible alternate 
conformation for the ring, however, the electron density is not 
clear enough to confidently model two alternate conformations 
for the ligand. 
The 4-fluorophenyl ring of 5 near the Glu165–Arg186 salt bridge 
is poorly defined by the initial difference electron density. 
Refinement of the model with the ligand 5 in place, but excluding 
the 4-fluorophenyl ring near Glu165–Arg186, results in additional 
difference electron density that indicates the general location of 
the ring, and refinements with the ring included in the model 
resulted in weak 2mFo−DFc electron density (0.7 σ) that supports 
the location of the ring. However, there is clearly a higher degree 
of disorder for this part of the ligand. This may initially appear 
counter-intuitive as known ligands with aromatic groups near the 
Glu165–Arg186 salt bridge region of galectin-3 have shown 
enhanced affinities (for example the diamido-
thiodigalactosides[8a, 8b] and aromatic lactose 2-O-esters[15]). 
However, the interaction involves face-to-face stacking between 
the aryl-triazoles onto an extended surface of the π-system of 
the Glu165–Arg186 ion-pair, which could allow for the aryl-
triazole to position over different segments of the large π-system 
with retained interaction free energies. 
 
 
Figure 1. Difference electron density within the galectin-3 CRD binding sites 
showing bound A) 12, B) 4, and C) 5. Difference electron density calculated 
from refinement with the ligand (stick representation) omitted from the model 
(|Fo|-|Fc| αcalc
grey solvent-accessible surface. 
The triazole ring of compounds 4, 5, and 12 located above 
His158 is orientated with the nitrogens positioned towards 
Trp181, which allows for formation of a water-mediated 
hydrogen bond between the N2 of the triazole and the nitrogen 
atom of Trp181 (Figure 2 a-c). The triazole ring of compounds 4, 
5, and 12 located near the in-plane Glu165-Arg186 salt bridge 
shows two alternate conformations that stack face-to-face to the 
in-plane Glu165-Arg186 salt bridge. In the 12 and 5 complexes, 
the triazole nitrogens are directed towards Glu165, while in the  
ChemBioChem 10.1002/cbic.201600285
 







Figure 2. Galectin-3 CRD binding site interactions with A) 12, B) 4, and C) 5. 
H-bond interactions between ligand (yellow bonds) and protein/water (green 
bonds) are shown as dashed lines. 
 
Figure 3. Superimposed view of the galectin-3 CRD binding site in the region 
of Arg144 for the complex with 4, 5, and 12 (yellow), the 3’-(2,3,5,6-tetra-
fluoro-4-methoxybenzamido) LacNAc derivative (red, PDB ID: 1KJR), and 
lactose (blue, PDB ID: 3ZSJ). 
complex with 4 the ring is flipped with the triazole nitrogens 
close to Arg186. The orientation of one of the triazole rings in 12 
and 5 results in contacts with both Glu184 and Arg186, while in 
4 the triazole is in contact with Arg186 only. 
In all three galectin-3 complexes with 4, 5, and 12, the ligands 
induces a conformational change in Arg144 (Figure 3) similar to 
that reported for the galectin-3 CRD structure in complex with 3’-
(2,3,5,6-tetra-fluoro-4-methoxybenzamido)-LacNAc derivative 
(PDB ID: 1KJR).[7c] One of the terminal aromatic rings of the 
ligands 4, 5, and 12 fits into a pocket that is exposed by the 
Arg144 conformational change and move away from the protein 
surface and forms a face-to-face stacking interaction with 
Arg144 in a similar manner as observed for the corresponding 
complex with 3’-(2,3,5,6-tetra-fluoro-4-methoxybenzamido)-
LacNAc derivative. However, in the structures of the complexes 
with 4, 5, and 12, the additional length granted by the triazole 
linker allows the terminal aromatic rings to extend deeper into 
the pocket exposed by the Arg144 move, which allows for the 
formation of an additional contact with Ala146 that is not 
observed in the 3’-(2,3,5,6-tetra-fluoro-4-methoxybenzamido)-
LacNAc complex. Additionally, although the conformational 
change of Arg144 in the complexes with 4, 5, and 12 is overall 
similar to that earlier observed for 3’-(2,3,5,6-tetra-fluoro-4-
methoxybenzamido)-LacNAc derivative,[7c] small differences are 
apparent. The Arg144 has moved in the complexes with 4, 5, 
and 12 compared to the complex with the 3’-(2,3,5,6-tetra-fluoro-
4-methoxybenzamido)-LacNAc derivative  (1.5–2.0 Å ζ-carbon 
to ζ-carbon distance) such that the guanidino group maintains its 
position directly above the aromatic ring of the ligand (Figure 3). 
One thiophene ring of 12 is orientated to deeply bury the sulfur 
atom in the pocket exposed by the Arg144 move, as is the 
fluorine atom in the 3-fluorophenyl ring of 4. The SAD LLG map 
calculated for the 12 complex confirms the orientation of the 
thiophene ring showing a clear peak positioned at the location of 
the sulfur atom within the pocket near Arg144. The fluorine of 4 
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below Arg144 is situated at a distance of 3.9Å and 3.4Å and at 
angles of 155° and 147° from the backbone carbonyls of Arg144 
and Ile145, respectively, which suggests the formation of two 
orthogonal multipolar interactions.[16] The fluorine atom of the 4-
fluorophenyl ring in 5 is directed towards Gly238 and Ser237 
and makes contact with the α-carbon of Gly238 and is also 
positioned well for forming an orthogonal dipolar interaction with 
the Ser237 carbonyl (distance 3.6Å and angle 140°). 
Furthermore, the guanidinium ion of arginine side chains has 
been proposed to be highly fluorophilic, as fluorine atoms of 
fluorinated pharmaceuticals have been observed to be close to 
guanidinium moieties in proteins.[16a, 17] Finally, fluorination 
typically results in increased lipophilicity[16a, 17] and fluorinated 
hydrocarbons are in general poorly solvated in water,[18] which 
would support a conclusion that burying fluorinated lipophilic 
ligand parts is important for achieving high affinity of 4 and 5 for 
galectin-3. The equivalent of Arg144 is absent in some 
galectins[19] and consequently targeting ligand interactions to this 
region and engaging Arg144 through cation-π interactions is 
proposed as a means of enhancing galectin binding selectivity. 
 
Galectin-3 mutant studies 
The X-ray structures of galectin-3 revealed that the aryl-triazoles 
of 4, 5, and 12 stacked face-to-face onto two (Arg144 and 
Arg186) arginine guanidinium groups. In case of galectin-3, the 
two 3-fluorophenyl moieties of 4 have different stacking modes 
with the two Arg144 and Arg186: One 3-fluorophenyl moiety is 
stacked on top of Arg186 guanidinium group, while the other 3-
fluorophenyl moiety is inserted between the protein surface 
(backbone) and Arg144 guanidinium group (Figure 1b, 2b, and 
3). In order to obtain further understanding about the nature of 
the aryl-triazole arginine stacking interactions, we determined 
the affinity of 4 for four galectin-3 mutants, R144K, R144S, 
R186K, and R186S (Table 2). The R144S and R186S mutants 
were chosen because the side-chain is removed without 
introducing a very non-polar surface and the R144K and R186K 
mutants were chosen because the cationic nature of the side-
chain is retained while the planar π-system of the guanidino 
group is removed. The effect of the R144S mutant is minimal, 
which suggests that the stacking of Arg144 onto the 3-
fluorophenyl group of 4 does not contribute significantly to the 
free energy of binding, while the surface complementarity and 
interactions of the 3-fluorophenyl group with the rest of the 
protein surface remains essentially unchanged. 
 
Table 2. Dissociation constants (µM) for 4 against galectin-3 mutants 
determined with a competitive fluorescence anisotropy assay.
[12]
 
wt R144K R144S R186K R186S 
0.014±0.003 0.041±0.0045 0.017±0.0032 0.54±0.039 1.0±0.12 
 
 
The R144K mutant binds 4 only about 3-fold less well than wild-
type, which suggests that the lysine side-chain can, as an 
arginine side-chain, form cation-π interactions. However, in 
contrast to the arginine guanidine group, the lysine amino group 
obviously lacks a π-system and π-stacking capability may be the 
reason that the interaction with the 3-fluorophenyl group of 4 is 
possibly slightly less productive. The R186S mutant shows a 
large drop in affinity for 4, clearly revealing that a 3-fluorophenyl 
stacking interaction onto Arg186 is an important contributor to 
the high affinity of 4 for galectin-3. The Arg186 side-chain 
guanidinim ion is, in contrast to the Arg144 side-chain, involved 
in an extensive network of in-plane bi-furcated ion-pairs (Figure 
2), which form an extended π-system surface onto which a 3-
fluorophenyl stacks in analogy with e.g. the acetamido group of 
N-acetyl-lactosamine[7c] and aromatic rings of 2-O-benzoyl 
lactose derivatives.[15] In the mutant R186S this extended π-
system of bi-furcated ion-pairs is interrupted and the 3-
fluorophenyl cannot form a beneficial stacking interaction. 
Instead, a poorly solvated cavity with poor complementarity to 
the 3-fluorophenyl group of 4 is present. Some binding affinity is 
regained in the R186K mutant as compared to the R186S 
mutant, which is presumably due the capability of the lysine 
side-chain to at least partly substitute and stabilize the Arg186 
side-chain’s key π-system-forming ion-pairing with the two 
surrounding Glu165 and Glu184 residues, as well as providing 
similar surface complementarity to the 3-fluorophenyl group of 4. 
In short, the high affinity of the 4-aryl-triazolyl thiodigalactosides, 
such as 4, 5, and 12, for galectin-3 can be hypothesized, 
according to X-ray structural analysis of galectin-3 complexes 
and galectin-3 mutant studies, originating from several factors. 
First, ideal surface complementarity between the proteins and 
ligands (Figure 1) are, not unexpectedly, critical as this 
maximizes dispersion forces and presumably also beneficial 
desolvation effects. Stacking between galectin arginine side 
chain guanidinium functionalities and ligand phenyl-triazole 
moieties are probably important, as are fluorine orthogonal 
dipolar interactions[16c] with backbone carbonyls. Hence, while 
the core thiodigalactoside disaccharide mimics natural 
disaccharide ligand fragments (e.g. lactose and LacNAc) in 
terms of affinity contributions and structure, the appended non-
carbohydrate aryl-triazole moieties engage in galectin-ligand 
interactions not seen in natural lectin-ligand complexes (i.e. 
predominantly hydrogen bonding and CH-π interactions), 
resulting in drastic affinity enhancements and enhanced 
selectivities. 
Having discovered low-nM galectin antagonists, an important 
question of their efficiency for antagonizing galectin-glycoprotein 
interactions in biological systems was addressed with compound 
4 in two models. First, an in vitro cell assay was developed with 
the goal of gaining new knowledge about galectin-3 putative 
intracellular glycan-binding activities and possible effects in cells 
challenged with vesicle-damaging agents. Second, to achieve 
further understanding of, as well as quantifying, the effects of 
antagonizing galectin-3 in an in vivo mouse model of bleomycin-












Figure 4. Inhibition galectin-3 accumulation around amitriptyline (AMI)-
damaged vesicles in MCF-7 cells. Cells were treated with combinations of 10 
µM compound 4 and 10 or 50 µM amitriptyline for 24 hours, control cells were 
treated with 0.1% v/v DMSO. A) Galectin-3 staining was visualized with anti-
rat Alexa Fluor® 594 (red), whereas Hoechst (blue) was used to stain the 
nuclei. The immunofluorescence pictures displayed are representative for 
each treatment. Scale bars are equivalent to 20 µm. Small square inserts 
show which areas is magnified in each large square insert. B) The number of 
galectin-3 dots were counted manually using ImageJ in four different images 
for each experimental condition, and given as mean ± SEM. Each data set 
represents ~250 cells. **P<0.01, ***P < 0.001, Student’s t-test. 
Intracellular inhibition by galectin-3 antagonist in an 
amitriptyline-induced vesicle damage assay 
Galectin accumulation around damaged vesicles in response to 
challenge by bacteria or chemical agents has been 
demonstrated in several studies and the formation of galectin-
3[20] or galectin-8[21] puncta have been proposed as a novel 
marker for vesicular insult, regardless of the insult being of a 
bacterial[20b, 21] or chemical origin[20a]. Galectin-3 accumulation 
around damaged vesicles has, in addition, been shown to 
depend on glycan-binding, either by knock-down of certain 
glycosyltransferases[20b] or via knock-in of a galectin-3 mutant 
(R186S) with severely reduced affinity for endogenous 
glycans[20a].  Antagonizing effects on such glycan binding-
dependent galectin-3 events on damaged vesicles[20b] could 
provide qualitative information on intracellular availability and 
activity of antagonists, such as compound 4. Cationic 
amphiphilic drugs, including the tricyclic antidepressant 
amitriptyline, induce phospholipidosis and are speculated to 
accumulate in acidic lysosomes, and induce vesicle damage in 
tumor cell lines.[20a, 22] We postulated that treatment of cells with 
amitriptyline would induce formation of galectin-3 puncta in a 
similar fashion as other vesicular damaging agents, such as 
glycyl-l-phenylalanine 2-naphthylamide[21] and l-leucyl-l-leucine 
methyl ester[23]. Amitriptyline has the advantage of being more 
stable under the experimental conditions used and does not 
degrade in solution as e.g. glycyl-l-phenylalanine 2-
naphthylamide. Furthermore, amitriptyline does not require the 
use of DMSO as co-solvent for solubilize the more commonly 
used peptidic vesicular damaging agents. Indeed, treating breast 
carcinoma MCF-7 cells with amitriptyline resulted in distinct 
accumulation of galectin-3 into vesicle-associated puncta, 
hypothetically within galectin-3:glycoprotein lattices, in a dose-
dependent manner (Figure 4a and b). Co-treatment with 10 µM 
compound 4 and 10 µM or 50 µM amitriptyline resulted in a 
significant reduction in the number of galectin-3 dots compared 
to amitriptyline treatment alone (Figure 4a and b), which strongly 
supports that compound 4 can act as an intracellular antagonist 
for galectin-3 in cell culture systems. The experimental 
concentration of 4 was selected to achieve a significant effect 
and possibly reflects a relatively slow cellular uptake and 
intracellular concentration increase of 4 sufficient to block 
intracellular galectin-3. 
 
Pharmacological intervention in a bleomycin-induced lung 
fibrosis mouse model 
Galectin-3 has been shown to promote both macrophage M2 
polarization[5b] and myofibroblast activation,[6b] i.e. in two key pro-
fibrotic cell types. In the case of macrophage M2 polarization, 
galectin-3 association with CD98 on the macrophage cell 
surface, presumably within lattices, was shown to be a plausible 
molecular mechanism for regulating M2 activation via 
phosphatidylinositol 3-kinase (PI3K) activation.[5b] Analogously, 
transforming growth factor-ß (TGF-ß) receptor II has been 
shown to bind galectin-3 on cell surfaces, which was suggested 
to be a critical molecular mechanism for inducing myofibroblast 
activation.[6b] Furthermore, in vivo an intratracheal single-dose of 
the galectin-3 antagonist 4 (10 µg per mouse, 500 µg/kg) was    
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Figure 5. Effects of pirfenidone and 4 on bleomycin-induced lung fibrosis in 
mice. A) Total lung collagen, B) Histological inflammatory score, C) 
Histological fibrosis score. Results represent the mean ± SEM of n=8 mice per 
group. (* P<0.03, **P<0.05, ***P<0.01 statistically different from bleomycin 
control). D) Representative Masson’s trichrome stained sections of mouse 
lung from uninjured saline control, bleomycin control and bleomycin treated 
with oral pirfenidone (200 mg/kg) or intratracheal 4 (500 µg/kg). 
 
Figure 6.  Effects of pirfenidone and compound 4 on BAL (bronchoalveolar 
lavage) fluid parameters in bleomycin-induced lung fibrosis in mice.  Total 
protein measured by BCA reagent, MCP-1, and galectin-3 in BAL fluid and 
serum were measured by ELISA. Results represent the mean ± SEM of n=8 
mice per group. (* P<0.05, statistically different from bleomycin control). 
demonstrated to display an anti-fibrotic effect in a bleomycin-
induced lung fibrosis mouse model.[6b] Hence, compound 4 can 
be hypothesized to possess dual anti-fibrotic effects by 
disrupting lattices with CD98 on M2 macrophages and with TGF-
ß-RII on myofibroblasts and associated pro-fibrotic signaling. 
However, the single-dose experiment left questions unanswered 
concerning the in vivo dose-response efficacy of compound 4 
and how this compared to alternative anti-fibrotic agents. Hence, 
we conducted a dose-response study of therapeutic 
administration of compound 4 in this model, in comparison with 
pirfenidone, one of only two recently approved drugs for treating 
idiopathic pulmonary fibrosis (IPF). Mice (n=8) received 
bleomycin sulphate (1.65 mg/kg intratracheally), resulting in 
inflammation and subsequent fibrosis development, followed by 
either 200 mg/kg pirfenidone twice daily orally from days 18-24 
or compound 4 at 500, 150, 50 or 5 µg/kg intratracheally as a 
single administration every second day (days 18, 20, 22 and 24). 
Lung collagen content and histopathology was determined on 
day 26.  Pirfenidone (200mg/kg) significantly reduced 
bleomycin-induced collagen accumulation from 670±77 to 
375±53 μg collagen/lobe (P<0.01), as did 500 and 150 µg/kg of 
compound 4 (355±46 and 546±22 μg collagen/lobe P<0.01, 
P<0.03, respectively) (Figure 5).  In addition, compound 4 at 500 
and 150 µg/kg doses and pirfenidone significantly decreased the 
fibrosis score.  Hence, when delivered directly into the lung, 
compound 4 achieves efficacy at much lower concentrations 
compared to orally delivered pirfenidone. The lower dose 
needed with administration of 4 could be due to the, not 
unexpectedly, improved lung targeting by intratracheal 
administration in combination with the high affinity of 4 for the 
target galectin-3 protein shown to be a key regulator of fibrosis 
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biochemistry. Lung availability of an orally administered 
compound is likely to be lower than that of an intratracheally 
administered compound, which may at least partly explain the 
need for a higher dose of oral pirfenidone to achieve the same 
efficacy as intratracheal 4. In addition, compound 4 did not 
reduce protein in the BAL (bronchoalveolar lavage) fluid – an 
indication of vascular leakage – but both pirfenidone and 
compound 4 reduced MCP-1 (monocyte chemoattractant 
protein-1) levels (Figure 6).  Compound 4 did not produce a 
clear significant decrease in galectin-3 levels in BAL fluid or 
serum. The absence of a significant decrease of galectin-3 in 
BAL fluid is likely due to the fact that BAL fluid samples are from 
whole lung and not only the fibrotic area. As non-fibrotic tissue 
has a background expression of galectin-3 this will influence the 
total galectin-3 levels in BAL fluid samples, therefore BAL fluid 
galectin-3 analysis may be underestimating the actual 
concentration of galectin-3 in the diseased areas of the lung. 
Conclusions 
Highly potent galectin-1 and 3 antagonists were discovered 
through synthesis optimization, and structural analysis of double 
C3 aryl-triazolyl-substituted thiodigalactosides. Low nM-affinities 
were reached for galectin-1 and 3 and some compounds 
displayed selectivity for individual galectins. Structural and 
mutational studies showed evidence that the exceptional affinity 
enhancement originated largely from the aryl-triazole moieties 
forming stacking interactions with protein π-systems (arginine 
side chains unpaired or ion-paired with glutamate or aspartate 
carboxylates) and in some cases fluorine-derived orthogonal 
multipolar interactions that endogenous glycoconjugate glycans 
do not form. The nature of the aryl-triazole moieties has a 
significant influence over galectin sub-type selectivities, which 
could also be explained by small, but significant, differences 
revealed in the structural studies. Overall, the results 
corroborate the promising strategy for discovery of high-affinity 
and selective lectin antagonists by exploring non-carbohydrate 
structural elements forming interactions that glycoside fragments 
of endogenous glycoconjugate ligands do not form with lectins. 
Hence, drug development targeting lectins may not necessarily 
involve a strategy of multimerizing ligands and antagonists to 
achieve sufficient affinities and the major challenges concerning 
pharmacokinetics, bioavailability, and toxicity/immunogenicity 
associated with multivalent antagonists may be avoided. 
One antagonist (4) was evidenced to have intracellular 
availability and activity as it blocked amitriptyline-induced vesicle 
damage in breast carcinoma MCF-7 cells. While it still remains 
to be answered which glycoprotein binding partner is involved in 
the galectin-3 accumulation on damaged vesicles, the lysosome 
associated membrane proteins LAMP-1 and LAMP-2 may be 
candidates for this role as they have been shown to be galectin-
3 ligands on the surface of tumor cells[24] and are thus possible 
candidate glycoprotein ligands in our model. Importantly, these 
observations suggest that intracellular galectin-3 glycoprotein-
binding events occur and may be biologically relevant. Targeting 
such interactions with synthetic antagonists may be a viable 
strategy, although PK-ADMET properties obviously have to be 
improved for intracellular/systemic availability and therapeutic 
applications. 
Furthermore, intratracheally delivered compound 4 attenuated 
bleomycin-induced lung fibrosis in a mouse model in a dose-
dependent manner and possessed efficacy at significantly lower 
doses than the approved oral anti-fibrotic pirfenidone and thus 
compared favorably with pirfenidone. This may further support a 
dual molecular mechanistic hypothesis in which galectin-3-
promoted macrophage and myofibroblast activation results in 
sustained pro-fibrotic cell signaling and scar formation.  
Finally, five-membered aromatic heterocycles are common 
structural elements in many drugs and 1,2,3-triazoles in 
particular are readily synthesized, which render the compounds 
herein as promising leads for the development of novel galectin-
targeting therapeutics that disrupt cellular signal-sustaining 
galectin-3 lattices as well as highly valuable tools for studying 
galectin biology and molecular mechanisms. 
Experimental Section 
Expression constructs, expression, and purification of recombinant 
galectins  
Human galectin-1,[25] galectin-2,[26] galectin-3,[27] galectin-4N,[12a] galectin-
4C,[12a] galectin-8N,[13b] and mouse galectin-7[28] were expressed and 
purified as earlier described. Human galectin-9N and galectin-9C were 
produced in E. coli BL21Star (DE3) cells (Invitrogen) and purified by 
affinity chromatography on lactosyl-Sepharose essentially as described 
for galectin-8.[13b] DNA encoding the genes of human galectin-9N and 
galectin-9C were cloned into the pET-32 Ek/LIC vector (Novagen, 
Madison, WI) according to the manufacturer’s instructions. Briefly, 
I.M.A.G.E. clone 2208156 (ATCC) was used as template together with 
the following polymerase chain reaction (PCR) primers. The vector used 
for galectin-9N encoded the N-terminal 170 amino acids of galectin-9 and 
thioredoxin with the primers forward: 5`- GAC GAC GAC AAG ATG ATG 
GGT TCA GCG GTT CCC AGG-3´, forward 2: 5´- GAG GAG AAG CCC 
GGT TCA GGA AAC AGA CAG GCT GGG AGA ACGG C-3´, and 
reverse: 5´- GAG GAG AAG CCC GGT GCC GCC TAT GTC TGC ACA 
TGG G-3´. The vector used for galectin-9C encoded the C-terminal 
amino acids 205-355 of galectin-9 and thioredoxin with the primers 
forward: 5´-GAC GAC GAC AAG ATG GGA CAG ATG TTC TCT ACT 
CCC-3´ and reverse: 5´-GAG GAG AAG CCC GGT GCG GCC TAT GTC 
TGC ACA TGG G-3´. The bacteria were grown (37°C, 200 rpm) in LB 
(Luria-Bertani) medium with ampicillin (1mg/l) overnight, followed by 
induction with 1mM isopropyl thio-β-D-galactoside (IPTG) for 4 h (29°C, 
200 rpm). The culture was centrifuged (15 min, 5000 rpm, 4°C) and the 
pellet was dissolved in 50 ml MEPBS (phosphate buffered saline with 2 
mM EDTA and 4 mM β-mercaptoethanol) and sonicated 10-20 x 30 s on 
ice. The sonicated bacteria were centrifuged (30 min, 12000 rpm, 4°C) 
and the supernatant was submitted to affinity chromatography using a 
lactosyl-Sepharose column washed with MEPBS and a pre-elution of 7,5 
mM lactose. The bound proteins were eluted with Lac-MEPBS (MEPBS 
with 150 mM lactose) as elution buffer. Removal of lactose was done by 
chromatography on a PD-10 column (Amersham Biosciences) and with 
repeated ultrafiltration using Centriprep (Amicon). 










Fluorescence polarization experiments were performed on a POLARStar 
plate reader with software FLUOstar Galaxy software or a PheraStarFS 
plate reader with software PHERAstar Mars version 2.10 R3 (BMG, 
Offenburg, Germany) and fluorescence anisotropy of fluorescein tagged 
probes measured with excitation at 485 nm and emission at 520 nm. Kd 
values were determined in PBS as previously described[12, 29] with 
specific conditions for each galectin as described below. Compounds 3-
10 were dissolved in neat DMSO at 100 mM and diluted in PBS to 3-6 
different concentrations to be tested in duplicates. Kd average and SEM 
were calculated from 4 to 25 single point measurements showing 
between 30-70% inhibition. 
Galectin-1 affinities: Experiments were done at 20°C with galectin-1 at 
0.50 µM and the fluorescent probe 3,3’-dideoxy-3-[4-(fluorescein-5-yl-
carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3’-(3,5-dimethoxy-
benzamido)-1,1’-sulfanediyl-di-β-D-galactopyranoside[25] at 0.10 µM.  
Galectin-2 affinities: Experiments were done at 20°C with galectin-2 at 
10 µM and the fluorescent probe 3,3’-dideoxy-3-[4-(fluorescein-5-yl-
carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3’-(3,5-dimethoxy-
benzamido)-1,1’-sulfanediyl-di-β-D-galactopyranoside at 0.10 µM. 
Galectin-3 affinities: Experiments were done at 20°C with galectin-3 at 
0.20 µM and the fluorescent probe 3,3’-dideoxy-3-[4-(fluorescein-5-yl-
carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3’-(3,5-
dimethoxybenzamido)-1,1’-sulfanediyl-di-β-D-galactopyranoside at 0.02 
µM or with galectin-3 at 1.0 µM and 2-(fluorescein-5/6-yl-carbonyl)-
aminoethyl 2-acetamido-2-deoxy--D-galactopyranosyl-(1–3)-[-L-
fucopyranosyl-(1-2)]-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside[12] 
at 0.10 µM.  
Galectin-4N affinities: Experiments were done at 20°C with galectin-4N 
at 3.0 µM and the fluorescent probe 3,3’-dideoxy-3-[4-(fluorescein-5-yl-
carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3’-(3,5-dimethoxy-
benzamido)-1,1’-sulfanediyl-di-β-D-galactopyranoside at 0.10 µM. 
Galectin-4C affinities: Experiments were done at 20°C with galectin-4C 
at 0.50 µM and the fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-
aminoethyl 2-acetamido-2-deoxy--D-galactopyranosyl-(1–3)-[-L-
fucopyranosyl-(1-2)]-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside at 
0.1 µM.  
Galectin-7 affinities: Experiments were done at 4°C with galectin-7 at 
2.00 µM and the fluorescent probe -D-galactopyranosyl(1—4)-2- 
acetamido-2-deoxy--D-glucopyranosyl(1—3)--D-galactopyranosyl(1—
4)-(N1-fluorescein-5-yl-carbonylaminomethylcarbonyl)--D-
glucopyranosylamine[30]  at 0.1 µM. 
Galectin-8N affinities: Experiments were done at 20°C with galectin-8N 
at 0.40 µM and the fluorescent probe 2-(fluorescein-5-yl-
carbonylamino)ethyl -D-galactopyranosyl(1—4)-2-acetamido-2-deoxy--
D-glucopyranosyl(1—3)--D-galactopyranosyl(1—4)--D-
glucopyranoside[13b] at 0.1 µM. 
Galectin-9N affinities: Experiments were done at 20°C with galectin-9N 
at 1.0 µM and the fluorescent probe 2-(fluorescein-5-yl-
carbonylamino)ethyl -D-galactopyranosyl(1—4)-2-acetamido-2-deoxy--
D-glucopyranosyl(1—3)--D-galactopyranosyl(1—4)--D-
glucopyranoside at 0.1 µM. 
Galectin-9C affinities: Experiments were done at 20°C with galectin-9C 
at 2.0 µM and the fluorescent probe 3,3’-dideoxy-3-[4-(fluorescein-5-yl-
carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3’-(3,5-dimethoxy-
benzamido)-1,1’-sulfanediyl-di-β-D-galactopyranoside at 0.10 µM. 
Galectin-3 R144S affinities: Experiments were done at 20°C with 
galectin-3 R144S at 0.30 µM and the fluorescent probe 2-(fluorescein-
5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy--D-galactopyranosyl-
(1–3)-[-L-fucopyranosyl-(1–2)]-β-D-galactopyranosyl-(1–4)-β-D-
glucopyranoside at 0.02 µM.  
Galectin-3 R144K affinities: Experiments were done at 20°C with 
galectin-3 R144K at 0.40 µM and the fluorescent probe 2-(fluorescein-
5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy--D-galactopyranosyl-
(1–3)-[-L-fucopyranosyl-(1–2)]-β-D-galactopyranosyl-(1–4)-β-D-
glucopyranoside at 0.02 µM.  
Galectin-3 R186S affinities: Experiments were done at 20°C with 
galectin-3 R186S at 3.50 µM and the fluorescent probe 2-(fluorescein-
5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy--D-galactopyranosyl-
(1–3)-[-L-fucopyranosyl-(1–2)]-β-D-galactopyranosyl-(1–4)-β-D-
glucopyranoside at 0.1 µM.  
Galectin-3 R186K affinities: Experiments were done at 20°C with 
galectin-3 R186K at 0.90 µM and the fluorescent probe -D-
galactopyranosyl(1—4)-2- acetamido-2-deoxy--D-glucopyranosyl(1—3)-
-D-galactopyranosyl(1—4)-(N1-fluorescein-5-yl-
carbonylaminomethylcarbonyl)--D-glucopyranosylamine at 0.1 µM.  
Crystallization 
Compounds 4, 5, and 12 were prepared in the galectin-3 crystallization 
conditions by initially solubilizing in 55% w/v polyethylene glycol (PEG 
6000), before addition of other crystallisation reagents to give a final 
concentration of 20 mM of 4, 5, and 12 in the galectin-3 crystallisation 
condition (31% w/v PEG 6000, 100 mM Tris-HC pH 7.5, 100 mM MgCl2 
for galectin-3). Galectin-3-CRD lactose or galactose co-crystals 
(prepared as previously described[31]) were soaked for 2–8 days in drop 
containing a 1:1 ratio of the ligand-containing crystallisation condition and 
20 mg/mL human galectin-3-CRD in 10 mM Tris-HCl pH 7.5 (pre-
equilibrated co-crystallisation drops that had not produced crystals). 
X-ray diffraction analysis and structure determination 
X-ray diffraction data sets were collected at room temperature from 
human galectin-3-CRD crystals mounted in 0.7 mm quartz capillaries on 
a ProteumR (Bruker AXS, Madison, WI, USA) diffractometer with a 
MacScience M06XCE rotating-anode generator (wavelength 1.5418 Å) 
equipped with a SMART6000 CCD detector. X-ray diffraction data were 
integrated using SAINT (Bruker AXS, Madison, WI, USA) and scaled and 
merged using SCALA[32] within the CCP4 suite of crystallographic 
software.[33] Structures were solved by initial rigid body refinement using 
a previously published galectin-3-CRD structure (1A3K),[34] with ligand 
and waters removed, as the initial model. TLS and restrained refinement 
was performed using REFMAC5.[35] Anomalously scattering elements 
were identified using single-wavelength anomalous dispersion log-
likelihood gradient maps (SAD LLG maps); calculated using Phaser [36] 
(in experimental phasing mode within CCP4) in the ‘SAD with molecular 
replacement partial structure’ mode with purely anomalous scatterers 
and zero LLG-map completion cycles using the current model and F+ 
and F− structure factor amplitudes as input. Visualization of electron 
density and model building was performed using Coot.[37] Ligand 
geometry topologies for refinement were initially created by REFMAC5 
within CCP4 (LIBCHECK) or using the Dundee PRODRG2 Server.[38] In 
most cases minor to moderate manual editing of the automatically 
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generated topologies was performed to ensure correct atom and bond 
types. Model validation and analysis was performed using MolProbity.[39] 
Figures were created using the CCP4 molecular-graphics project 
(CCP4MG).[40]  
Accession codes 
PDB: The atomic coordinates and structure factors of galectin-3 in 
complex with 4, 5, and 12 have been deposited with accession codes 
5E89, 5E8A, and 5E88, respectively. 
Site-directed Mutagenesis 
Mutants of human galectin-3 were made using the QuickChange® II site-
directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), 
produced in E.coli BL21Star (DE3) cells (Invitrogen, Lidingö, Sweden) 
and purified by affinity chromatography on lactosyl-Sepharose as 
previously described.[41] Mutagenic primers for PCR were as follows: Gal-
3R186K (AGA→AAA) sense (5´-CTG GGG AAG GGA AGA AAA ACA 
GTC GGT TTT CCC-3´) and antisense (5´-GGG AAA ACC GAC TGT 
TTT TCT TCC CTT CCC CAG-3´) and Gal-3R144K (AGA→AAA) sense 
(5´-GAA GCC CAA TGC AAA CAA AAT TGC TTT AGA TTT CCA AAG 
AG-3´) and antisense (5´-CTC TTT GGA AAT CTA AAG CAA TTT TGT 
TTG CAT TGG GCT TC-3´). Successful mutagenesis was confirmed by 
sequencing by GATC Biotech (Konstanz, Germany) in the forward 
direction from the T7 promotor primer and in the reverse direction from 
the pET-RP primer. Galectin-3 R144S and R186S were prepared as 
earlier reported.[41] 
Cell culture and immunocytochemistry 
MCF-7 cells were maintained in RPMI-1640 (Biochrom, Berlin, Germany) 
supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany), 
10 µg/mL insulin (Sigma-Aldrich, Stockholm, Sweden), 100 µg/mL 
streptomycin and 100 units/mL penicillin (Hyclone). The cells were kept 
in a 37 C humidified incubator supplied with 5% CO2 in air. For the 
experiments stock solutions of 4 mM compound 4 in 40% dimethyl 
sulfoxide (DMSO) was used, while for amitriptyline (Sigma-Aldrich) stock 
solutions of 20 mM was made in sterile water. Both compound 4 and 
amitriptyline were serially diluted in RPMI-1640 before treatment of cells, 
such that the DMSO concentration did not exceed 0.1% v/v.  MCF-7 (105 
cells) were seeded onto sterile coverslips (placed in multiwell plates) and 
cultured for 24 hours. Cells were then treated with either 10 or 50 µM 
amitriptyline either alone or in combination with 10 µM of compound 4 for 
24 hours. After fixation with 2% paraformaldehyde in phosphate-buffered 
saline (PBS) for 10 minutes, cells were permeabilized using 0.4% v/v 
Triton X-100 in PBS for 5 minutes. Non-specific binding was inhibited by 
blocking the cells with blocking buffer (1% w/v BSA, 0.1% v/v Tween 20 
in PBS) for 10 minutes. Cells were then incubated with rat anti-mouse 
galectin-3 antibody (anti-Mac-2[42]) in a humidified chamber for 1 hour at 
room temperature. After three washes with PBS, goat anti-rat Alexa 
Fluor® 594 (Invitrogen, Carlsbad, USA) was added. Hoechst (10 ng/mL) 
was used to stain the nuclei. Cells were visualized by obtaining z-stacks 
of high magnification single optical planes using a LSM510 confocal laser 
scanning microscope (Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany), conjugated with Hamamatsu R6357 (Hamamatsu Photonics 
K.K., Hamamatsu, Japan) photomultiplier. Galectin-3 dots were counted 
manually using ImageJ 1.47v and the plug-in Cell Counter (Wayne 
Rasband, National Institutes of Health, USA). Bar graphs representing 
galectin-3 dots/nuclei are expressed as mean values of different image 
areas ± SEM. For measuring statistical significance between a pair of 
data sets, Student’s t-test (two tailed, unpaired) was employed. P<0.05 
was considered to be significant. 
Bleomycin-induced fibrosis 
Bleomycin was purchased from Apollo Scientific and reconstituted in 
sterile saline at a concentration of 0.66 mg/mL and aliquots were stored 
at -20oC.  Pirfenidone was purchased from Tocris Biochemicals and was 
dissolved in 0.5% carboxymethyl cellulose (Sigma Aldrich) to a 
concentration of 20 mg/mL.  Compound 4 was dissolved in 100% DMSO 
at a concentration of 10 mg/mL and aliquots stored at -20oC.  For each 
day, compound 4 for instillation was diluted in sterile saline to give a final 
concentration of DMSO in the instillate of 2%. Female C57/Bl6 mice 10 
weeks of age were purchased from Charles River and were maintained in 
12-hour light/12-hour dark cycles with free access to food and water. All 
procedures were performed in accordance with Home Office guidelines 
(Animals (Scientific Procedures) Act 1986). 
Mice were randomised into 8 treatment groups (n=8) and were 
saline. Mice were monitored closely over the next 26 days.  Pirfenidone 
treated mice received pirfenidone 200 mg/kg by oral gavage twice daily 
from days 18-24.  Mice treated with compound 4 
intratracheally commencing day 18 every 48 hours for a total of 4 
administrations.  Control mice received vehicle (2% DMSO). Mice were 
culled on day 26.  The lungs were perfused (via the right ventricle) with 5 
ml saline and the lungs lavaged with 3 x 0.8 mL PBS containing 1 mM 
EDTA.  BAL cells were combined and pelleted and lavage fluid from the 
first lavage was snap frozen.  The lungs were removed and the entire left 
lobe removed and stored at -80oC for analysis of total collagen.  Two 
upper right lobes were removed and snap frozen and stored at -80oC for 
subsequent RNA analysis.  The remaining lung was inflated with 10% 
formalin and fixed for 24 hours prior to removal into 70% ethanol before 
embedding in paraffin wax for histological examination. 
Total lung collagen 
Frozen left lobes were thawed, weighed and minced finely with scissors 
and placed in 5ml of 3mg/ml pepsin in 0.5M acetic acid.  Samples were 
incubated for 24 hours at 4oC and 0.2 mL of cleared extract was 
incubated with 0.8 mL Sircol reagent (Biocolor) for 60 minutes at room 
temperature.  Collagen was sedimented by centrifugation at 13000 rpm 
for 5 minutes and the pellets resuspended in 0.5 mL of 0.5M NaOH.  
Samples were examined for absorbance at 560 nm with reference to a 
collagen standard curve. 
Estimation of vascular leakage 
Vascular leakage was determined by measuring total protein in the 
lavage fluid by BCA assay (Pierce) using bovine serum albumin as 
standard. 
Histological lung inflammation and fibrosis score 
Fibrosis and histological score was carried out in Masson’s trichrome 
stained sections.  Inflammation (peribronchiolar, perivascular, and 
alveolar wall thickness) scored in > 5 random fields at magnification X630 
using the following system (peribronchiolar and perivascular, 1 = no cells, 
2 = <20 cells, 3 = 20 – 100 cells, 4 = > 100 cells; alveolar wall thickness, 
1 = no cells, 2 = 2 – 3 cells thick, 3 = 4 – 5 cells thick, 4 = > 5 cells thick).  
The combined inflammatory score is the sum of these scores.  Fibrosis 
score was evaluated as the area of the section positively stained for 
collagen (1 = none, 2 = <10%, 3 = < 50%, 4 = > 50%).  Only fields where 
the majority of the field is composed of alveoli were scored. 
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Determination of galectin-3 levels in BAL and serum by ELISA 
Samples of BAL fluid and serum were assayed for galectin-3 and MCP-1 
levels by ELISA (R&D systems).. 
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